

ASX RELEASE

Volpara CEO to present at Mammographic Density Symposium in Brisbane

Wellington, NZ, 22 March 2017: Volpara Health Technologies ("Volpara"; ASX: VHT), a digital health company focused on early detection of breast cancer by improving quality of screening, is pleased to announce Dr Ralph Highnam, CEO of Volpara Health Technologies will be speaking at the Mammographic Density Symposium, to be held in Brisbane on 23rd March 2017.

The symposium, is part of a two-day event, which comprises an open public lecture being held on the evening of 22nd March 2017 at the Institute of Health and Biomedical Innovation, to be delivered by leading mammographic density researcher Professor John Hopper and consumer advocate Gerda Evans.

World renowned breast cancer and density awareness advocate Dr Nancy Capello, will deliver the opening address at the symposium. Dr Capello is the founder and Executive Director of Are You Dense, which educates the public and about the risks and screening challenges of dense breasts. Her advocacy inspired the first Mammographic Density law in Connecticut, USA in 2009.

"This is a very important forum that brings together leading researchers of breast density in Australia, at a time when the link between density, risk of cancer and detection is being better understood. The debate is now shifting away from the need to gather evidence, to the need to inform women of their breast density, and tonight's public lecture and the presence of Nancy Capello at the symposium tomorrow, will propel this issue further into the public realm," said Dr Ralph Highnam, CEO of Volpara Health Technologies.

The event is organised by INFORMD, a group of researchers who are investigating different aspects of breast density and who are recognised by their peers as experts in the field of breast density.

For further information on the event visit: <http://www.informd.org.au/events.html>

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on automated, objective measurements of breast density and quality.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services.

VHT, an ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, has customers and/or research projects in 35 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
t: +61 3 9866 4722